New Recruiting Trial: Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

WHY IT MATTERS

This trial offers a targeted treatment option specifically designed for infants and toddlers with NTRK- or ROS1-fused CNS tumors, a group that has historically had very limited treatment options and poor outcomes.

Researchers at St. Jude Children's Research Hospital are testing a drug called entrectinib to treat very young children (under 3 years old) who have brain or spinal cord tumors caused by changes in specific genes called NTRK1, NTRK2, NTRK3, or ROS1. This is a Phase 2 trial, meaning they've already tested the drug in a small group and now want to see if it works well in more patients. The trial is now accepting new patients and is expected to start in April 2026.

NCT ID: NCT06528691 Title: Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors Status: RECRUITING Phase: PHASE2 Sponsor: St. Jude Children's Research Hospital Start date: 2026-04-01 URL: https://clinicaltrials.gov/study/NCT06528691 Source: UniteRare clinical trials database

YOU CAN ACT ON THIS

If your child has been diagnosed with an NTRK- or ROS1-fused brain or spinal cord tumor and is under 3 years old, contact St. Jude Children's Research Hospital now to ask about enrollment eligibility and next steps.